Literature DB >> 29221254

Recent studies move closer to answering questions about sequential therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Tetsu Kobayashi1, Hajime Fujimoto1, Corina D'Alessandro-Gabazza2, Esteban C Gabazza2, Osamu Hataji3.   

Abstract

Entities:  

Year:  2017        PMID： 29221254      PMCID： PMC5708428          DOI： 10.21037/jtd.2017.08.114

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  29 in total

1.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Authors:  Young Lim Choi; Manabu Soda; Yoshihiro Yamashita; Toshihide Ueno; Junpei Takashima; Takahiro Nakajima; Yasushi Yatabe; Kengo Takeuchi; Toru Hamada; Hidenori Haruta; Yuichi Ishikawa; Hideki Kimura; Tetsuya Mitsudomi; Yoshiro Tanio; Hiroyuki Mano
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.

Authors:  Francesco Facchinetti; Yohann Loriot; Mei-Shiue Kuo; Linda Mahjoubi; Ludovic Lacroix; David Planchard; Benjamin Besse; Françoise Farace; Nathalie Auger; Jordi Remon; Jean-Yves Scoazec; Fabrice André; Jean-Charles Soria; Luc Friboulet
Journal:  Clin Cancer Res       Date:  2016-07-11       Impact factor: 12.531

3.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Authors:  Hiroshi Sakamoto; Toshiyuki Tsukaguchi; Sayuri Hiroshima; Tatsushi Kodama; Takamitsu Kobayashi; Takaaki A Fukami; Nobuhiro Oikawa; Takuo Tsukuda; Nobuya Ishii; Yuko Aoki
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

4.  A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.

Authors:  Takaaki Sasaki; Jussi Koivunen; Atsuko Ogino; Masahiko Yanagita; Sarah Nikiforow; Wei Zheng; Christopher Lathan; J Paul Marcoux; Jinyan Du; Katsuhiro Okuda; Marzia Capelletti; Takeshi Shimamura; Dalia Ercan; Magda Stumpfova; Yun Xiao; Stanislawa Weremowicz; Mohit Butaney; Stephanie Heon; Keith Wilner; James G Christensen; Michel J Eck; Kwok-Kin Wong; Neal Lindeman; Nathanael S Gray; Scott J Rodig; Pasi A Jänne
Journal:  Cancer Res       Date:  2011-07-26       Impact factor: 12.701

Review 5.  W'ALK' Into the Next Stage.

Authors:  Gouji Toyokawa; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Clin Lung Cancer       Date:  2016-10-26       Impact factor: 4.785

6.  Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Authors:  D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

Review 7.  Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.

Authors:  Hiroyuki Mano
Journal:  Cancer Sci       Date:  2008-11-20       Impact factor: 6.716

8.  Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.

Authors:  Jeff Elleraas; Jason Ewanicki; Ted W Johnson; Neal W Sach; Michael R Collins; Paul F Richardson
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-16       Impact factor: 15.336

9.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

10.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316
View more
  1 in total

Review 1.  An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Authors:  Tamkin Ahmadzada; Steven Kao; Glen Reid; Michael Boyer; Annabelle Mahar; Wendy A Cooper
Journal:  J Clin Med       Date:  2018-06-15       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.